CONTEXT THERAPEUTICS INC.

CHARTER OF THE RESEARCH AND DEVELOPMENT COMMITTEE OF THE BOARD OF DIRECTORS

(Adopted on July 16, 2026)

PURPOSE

The purpose of the Research and Development Committee (the "**Committee**") of the Board of Directors (the "**Board**") of Context Therapeutics Inc. (the "**Company**") is to assist the Board's oversight of the Company's research and development activities and to advise the Board with respect to scientific, development and regulatory topics.

COMPOSITION

1. Membership and Appointment. The Committee shall consist of such number of directors as the Board shall from time to time determine. Members of the Committee shall be appointed by the Board to serve for such terms as the Board may determine and may be removed by the Board in its discretion (with or without cause).

2. Qualifications. Each member of the Committee shall have such qualifications as are established by the Board from time to time, or as required by the NASDAQ Rules, applicable law or the rules and regulations of the U.S. Securities and Exchange Commission (the "**SEC**").

3. Chairperson. The Board may designate a chairperson of the Committee. In the absence of that designation, the Committee may designate a chairperson by majority vote of the Committee members, provided that the Board may replace any chairperson designated by the Committee at any time.

RESPONSIBILITIES

The following are the principal recurring responsibilities of the Committee. The Committee may perform such other functions as are consistent with its purpose and applicable law, rules and regulations and as the Board deems appropriate. In carrying out its responsibilities, the policies and procedures of the Committee should remain flexible, in order to best react to changing conditions and circumstances.

1. Research and Development Matters. The Committee shall function as a knowledgeable and objective group to consider and report periodically to the Board, as requested by the Board, on matters relating to the Company's research and development initiatives. The Research and Development Committee shall:

    - Review the overall scientific, research and development strategy of the Company;
    - Review the Company's research and development programs;
    - Review with management the Company's assessment of its major risk exposures in areas relating to Company's clinical development, clinical trial safety and its product candidate pipeline; and

- Review and advise the Board on the scientific, medical, research and development aspects of any proposed material transactions.
- Perform such other duties as may be delegated from time to time by the Board.

2. Committee Charter Review. The Committee shall review and reassess the adequacy of this charter annually and shall submit any recommended changes to the charter to the Board for approval. The Company shall make a copy of this charter publicly available on its website and shall disclose how to access the Committee's charter in its proxy statement.

3. Performance Review. The members of the Committee shall review and assess the performance of the Committee on an annual basis in fulfilling its duties and responsibilities under this charter.

MEETINGS AND PROCEDURES

1. Meetings.

    - The Committee will meet as often as it deems necessary or appropriate, provided the Committee shall meet at least once each calendar year. Meetings will be held at such times and places as the Committee determines. The Committee is governed by the same rules regarding meetings (including meetings in person or by telephone or other similar communications equipment), action without meetings, notice, waiver of notice and quorum and voting requirements as are applicable to the Board.

    - The Committee shall cause to be kept written minutes of its proceedings, which minutes will be filed with the minutes of the meetings of the Board.

    - The Committee may invite to its meetings any director, officer or employee of the Company and such other persons as it deems appropriate in order to carry out its responsibilities. The Committee may also exclude from its meetings any persons it deems appropriate in order to carry out its responsibilities, including non-management directors who are not members of the Committee.

2. Reporting to the Board of Directors. The Committee shall report regularly to the Board regarding its activities and recommendations.
3. Authority to Retain Advisors. The Committee shall have the authority to engage and terminate independent counsel, search firms or other advisors as it deems necessary or appropriate to carry out its duties. The Committee shall set the compensation and oversee the work of any such independent counsel, search firms or other advisors. The Company will provide appropriate funding, as determined by the Committee, to pay any outside advisors hired by the Committee and any administrative expenses of the Committee that are necessary or appropriate in carrying out its activities.
4. Subcommittees. The Committee may form subcommittees for any purpose that the Committee deems appropriate and may delegate to such subcommittees such power and authority as the Committee deems appropriate, subject to applicable law and NASDAQ Rules. If designated, each such subcommittee will establish its own schedule and maintain written minutes of its meetings, which minutes will be filed with the minutes of the meetings of the Board. The Committee shall not delegate to a subcommittee any power or authority required by law, regulation or listing standard to be exercised by the Committee as a whole. Any actions of a subcommittee shall be presented to the full Committee at its next scheduled meeting.

5. Compensation. Members of the Committee shall receive such compensation, including equity and/or fees, if any, for their service as Committee members as may be determined by the Board in its sole discretion.

****